Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products…more
Latest RNS from Hikma Pharmaceuticals PLC
- Hikma appoints Rebecca Hall as CFO
- board_changeDirectorate change
- interim_resultsHalf-year Financial Report
Analyst consensus: Buy
As of 6 Oct 2026, 11 analysts rate Hikma Pharmaceuticals PLC a Buy, with 91% buy ratings and a mean price target of 2,041p (range 1,738p–2,620p), +26% vs the current price.
Valuation vs peers
Peer-relative fair value estimate: 2,776p against a current price of 1,582p (+76%), based on EV/EBITDA.